Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias I: Introduction01:15

Dysrhythmias I: Introduction

Dysrhythmias refers to abnormalities in the heart's rhythm. They result from disruptions in the heart's electrical conduction system, which includes the sinoatrial(SA)node, atrioventricular(AV) node, the bundle of His, bundle branches, and Purkinje fibers.Definition and PathophysiologyDysrhythmias result from disorders of impulse formation, impulse conduction, or both. The heart contains specialized cells in the sinoatrial node, atrioventricular node, and the bundle of His and Purkinje fibers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Syncope in older patients : Who needs what and when?]

Herzschrittmachertherapie & Elektrophysiologie·2017
Same author

["It is not how old you are but how you are old"-Antiarrhythmic therapy in elderly patients].

Herzschrittmachertherapie & Elektrophysiologie·2017
Same author

[Innovations in anti-arrhythmia therapy of atrial fibrillation].

Herzschrittmachertherapie & Elektrophysiologie·2010
Same author

[Pulmonary vein isolation with multipolar ablation catheters for the treatment of paroxysmal atrial fibrillation].

Herzschrittmachertherapie & Elektrophysiologie·2009
Same author

[Atrial fibrillation ablation: who comes into consideration?].

Herzschrittmachertherapie & Elektrophysiologie·2009
Same author

[Atrial fibrillation update].

Herzschrittmachertherapie & Elektrophysiologie·2009
Same journal

[Extrasystoles in endurance athletes].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[AI-Assisted ECG diagnostics : Classical test statistics still apply].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Perioperative complications during transvenous pacemaker and defibrillator implantation].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Late complications after atrial fibrillation ablation : Diagnosis and management].

Herzschrittmachertherapie & Elektrophysiologie·2026
Same journal

[Position paper of the German Society of Cardiology-quality criteria for performing catheter ablation of atrial fibrillation: executive summary].

Herzschrittmachertherapie & Elektrophysiologie·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Dronedarone].

B-D Gonska1

  • 1St. Vincentius-Kliniken Karlsruhe, Med. Klinik III - Kardiologie, Angiologie, Intensivmedizin, Akademisches Lehrkrankenhaus der Universität Freiburg, Südendstrasse 32, 76137, Karlsruhe, Deutschland. prof.gonska@vincentius-ka.de

Herzschrittmachertherapie & Elektrophysiologie
|November 25, 2010
PubMed
Summary
This summary is machine-generated.

Dronedarone offers effective antiarrhythmic therapy for atrial fibrillation with a favorable side effect profile, making it suitable for outpatient use. This agent aims to match amiodarone

More Related Videos

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Related Experiment Videos

Last Updated: Jun 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) management requires effective antiarrhythmic agents.
  • Amiodarone is potent but associated with significant side effects.
  • There is a need for antiarrhythmic drugs with comparable efficacy and improved safety.

Purpose of the Study:

  • To evaluate dronedarone as a novel antiarrhythmic agent for atrial fibrillation.
  • To compare the efficacy and safety profile of dronedarone against existing therapies.
  • To assess dronedarone's suitability for outpatient management of AF.

Main Methods:

  • Dronedarone's chemical structure was modified from amiodarone by removing iodine and adding a methane-sulfonamyl group.
  • Clinical guidelines, such as those from the European Society of Cardiology, were reviewed for dronedarone's classification.
  • Patient tolerability and side effect profiles were assessed in the context of outpatient AF therapy.

Main Results:

  • Dronedarone is approved for AF therapy and rate control in tachyarrhythmic AF.
  • It demonstrates high antiarrhythmic potency while aiming to reduce amiodarone-related side effects, particularly thyroid issues.
  • European Society of Cardiology guidelines recognize dronedarone alongside other effective antiarrhythmic agents for pre-ablation use.

Conclusions:

  • Dronedarone is a well-tolerated antiarrhythmic medication.
  • Its improved side effect profile facilitates its use in an outpatient setting for atrial fibrillation patients.
  • Dronedarone represents a significant advancement in AF management, offering a safer alternative to traditional agents.